Model for detecting cervical cancer and cervical high-grade lesions and application

By constructing a machine learning model based on JAM3, PCDHGB7 and SORCS1 genes, we can detect cervical cancer and high-grade lesions, and solve the problem of poor overreferral and detection effects in cervical cancer screening in the prior art, achieving high sensitivity and high level of cervical cancer Specific cervical cancer screening, saving costs and time.

CN118969098AInactive Publication Date: 2024-11-15CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI +1

Patent Information

Application Number
CN202411104041.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Previous technology In cervical cancer screening, HPV virus nucleic acid testing has the risk of overreferral and treatment. Human gene methylation detection technology has not yet achieved stable and good detection results, and lacks non-invasive, rapid and accurate cervical cancer screening. Model.

Method used

Diagnostic models for cervical cancer and high-level cervical lesions are constructed based on logistic regression, support vector machine, random forest, neural network, LASSO regression or ridge regression models of JAM3, PCDHGB7 and SORCS1 genes. By detecting the methylation level of these genes, use Fewer markers detect cervical shedding cell samples to achieve early screening of high sensitivity and high specificity of cervical cancer and high-grade lesions.

Benefits of technology

This model can detect patients at risk of cervical cancer malignancy in the early stages of cancer, with high sensitivity and high specificity, saving costs and time, and providing more accurate cervical cancer screening support.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118969098A_ABST
    Figure CN118969098A_ABST
Patent Text Reader

Abstract

The invention relates to the field of molecular biological detection, in particular to the field of cervical cancer detection. The invention discloses a model for detecting cervical cancer and cervix high-level lesions. The model is a cervical cancer and cervix high-level lesion diagnosis model constructed by applying logistic regression, a support vector machine, a random forest, a neural network, LASSO regression or ridge regression models on the basis of a JAM3 gene, a PCDHGB7 gene and an SORCS1 gene. According to the model, the cervical exfoliated cells are used for detection, high sensitivity and specificity can be achieved, the aim of recognizing women really having the cervical cancer malignant transformation risk in the early stage is achieved, and cost and time are saved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of molecular biology detection, specifically, to the field of cervical cancer detection, and more specifically, to a model and use for detecting cervical cancer and high-grade cervical lesions. Background Art

[0002] HPV nucleic acid testing is the mainstream technology for initial screening of cervical cancer. However, more than 90% of HPV infections are transient and will clear up on their own within 1-2 years. Screening for cervical cancer only through HPV nucleic acid testing will increase the risk of over-referral and over-treatment, and will not make efficient use of medical and health resources. Finding key molecules that can be used for early screening and auxiliary diagnosis of cervical precancerous lesions and cervical cancer, and optimizing molecular detection pathways, are feasible and efficient ways to improve the effectiveness of cervical cancer screening.

[0003] Human gene methylation detection is currently a research hotspot in the field of cervical cancer screening technology. So far, more than 100 types of human gene methylation have been found to be closely related to the occurrence and development of cervical cancer. In order to balance the detection sensitivity and specificity, these genes are usually combined to develop cervical cancer screening technology. Affected by differences in the target genes contained in the combination, the number of target genes, and the molecular detection technology used, the existing human gene methylation combination screening technology has not yet achieved stable and good detection results. To date, no human gene-based methylation detection technology has been recommended by the screening guidelines of authoritative organizations around the world for large-scale cervical cancer screening practices.

[0004] This field urgently needs a non-invasive, rapid and more accurate cervical cancer screening model to provide technical support for improving the effectiveness of cervical cancer screening. Summary of the invention

[0005] In view of this, the present invention provides a model for detecting cervical cancer and high-grade cervical lesions:

[0006] The model is a diagnostic model for cervical cancer and high-grade cervical lesions constructed based on the JAM3 gene, PCDHGB7 gene and SORCS1 gene using logistic regression, support vector machine, random forest, neural network, LASSO regression or ridge regression model.

[0007] Furthermore, the cervical cancer and high-grade cervical lesions include cervical intraepithelial neoplasia grade 2 (CIN2), cervical intraepithelial neoplasia grade 3 (CIN3) and cervical cancer.

[0008] Furthermore, the model includes: a CIN2+ diagnostic model and / or a CIN3+ diagnostic model.

[0009] Furthermore, the CIN2+ diagnostic model is:

[0010]

[0011] Among them, X1 is the methylation level of the JAM3 gene; X2 is the methylation level of the PCDHGB7 gene; and X3 is the methylation level of the SORCS1 gene.

[0012] When the P value calculated by the prediction model is greater than or equal to 0.295, it is judged as positive; when it is less than 0.295, it is judged as negative.

[0013] Furthermore, the CIN3+ diagnostic model is:

[0014]

[0015] Among them, X1 is the methylation level of the JAM3 gene; X2 is the methylation level of the PCDHGB7 gene; and X3 is the methylation level of the SORCS1 gene.

[0016] When the P value calculated by the prediction model is greater than or equal to 0.103, it is judged as positive; when it is less than 0.103, it is judged as negative.

[0017] In the present invention, the term "CIN2+" includes cervical cancer, CIN3 and CIN2; the term "CIN3+" includes cervical cancer and CIN3.

[0018] In some specific embodiments, the methylation level of the JAM3 gene may be the methylation level of the region of the JAM3 gene as shown in SEQ ID NO: 1.

[0019] In some specific embodiments, the methylation level of the PCDHGB7 gene may be the methylation level of the region of the PCDHGB7 gene as shown in SEQ ID NO:2.

[0020] In some specific embodiments, the methylation level of the SORCS1 gene may be the methylation level of the region of the SORCS1 gene as shown in SEQ ID NO: 3.

[0021] The region shown in SEQ ID NO: 1 in the JAM3 gene, the region shown in SEQ ID NO: 2 in the PCDHGB7 gene, and the region shown in SEQ ID NO: 3 in the SORCS1 gene are a sequence of the CpG island in the promoter region of each gene.

[0022] Specifically, the SEQ ID NO: 1 region of the JAM3 (Genbank accession number: NC_000019.10) gene is as follows:

[0023] CAGCTTCCTCTGTCACCATGGTGCCGGCTCGGCTGGGCCCGGCGGTCGCCATGGTAACTGGGGCGGGTCGCAGGGTCCTGGCAGGCTGGGCGCATGCGCGCGGGGACTACAAGCCGCGCCGCGCTGCCGCTGGCCCCTCAGCAACCCTCGACATGGCGCTGAGGCGGCCACCGCGACTCCGGCTCTGCGCTCGGCTGCCTGACTTCTTCCTGCTGCTGCTTTTCAGGGGTGAGTTTGCGCGTTTCCGCTGTTGGGAGACTAGGGTCTGGGGGCGACGGAAGCAGAGCGGGCCGAAGCTGCTGGAGCCGGTCCGGGCGAGGATAGCGGTCCTGGCTCCGAGGGCTCCCGGGGTCCCGGGCCGGAGGGGCGGCGCGCGCCCGCGTCCCCGCAGCCAGGGCTGGGACTCGGGCCTGGCTAGGGCGGGGGCCCTGGGACGCCCGGCAGTTGGACCGGGGC

[0024] The SEQ ID NO:2 region of the PCDHGB7 (Genbank accession number: NC_000007.14) gene is shown below:

[0025] CTCGTAGTTTAAAAAAAATTCCTTGAAAGAGGTAGAGAAAAGTCAAGTTGCAGTCCCACACAGAGCCTCTGGGCGCCGCCGTCGGCCAGTGCAGAGCAAGCGCTGACGCCGGGGATCCCTCAGCCTCTAGCCTGGGATTCCCTGCGCAGCCAACAACAGAAAAGAAAACCAGCTCCCACACAGAGGCTCCCGGCTGCGCAGACCTTGCCCAGCACACCAGATTGCCAGCTCCGAGACCCGGGACTCCTCCTGTCCTGGGCCGAATGCTCTTTTAGCGCGGTAGAGTGCACTTTCTCCAACTGGAAAAGCGGGGACCCAGCGAGAACCCGAGCGAACGATGGGAGG

[0026] The region as shown in SEQ ID NO:6 in the SORCS1 (Genbank accession number: NC_000010.11) gene is shown below:

[0027] GCGGCACGAGCTCTGCGCTGGCGGCTGTGGGGGGCCGGCGCTCAGGACCCCAACTCCATCCAAGTTGCGCCGCGGTGGGGGCGGGCGGAGGCGGCCGGGCAGGTGGCGGCCGCTTGCCCGGGCTGGGCTTGTGCCGAGCGCGGTCCGGACGGAGCGAGCCGCCGCCGCGGGGGTGGAGCTGAGCTGAAGTCACTGGCGGAG

[0028] The model of the present invention uses fewer markers to detect cervical exfoliated cell samples, and can detect patients who are truly at risk of cervical cancer malignancy in the early stages of the carcinogenesis process. It has high sensitivity and high specificity, saving cost and time.

[0029] In the present invention, "CpG island" is the abbreviation of cytosine (C)-phosphate (p)-guanine (G), which refers to some regions rich in CpG dinucleotides on the genome, with a length of 300 to 3000 bp.

[0030] In some embodiments, the detection reagent of the present invention can be used to detect the methylation level of a CpG island on a corresponding gene or a sequence on a CpG island present in a sample.

[0031] In the present invention, "sample" refers to a biological sample selected from an individual, specifically, for example, selected from histological sections, tissue biopsy / paraffin-embedded tissues, etc., preferably a cervical exfoliated cell sample.

[0032] In the present invention, "detection reagent" refers to a reagent for detecting the methylation level of a gene in a sample, wherein the methylation level is measured by amplification-sequencing, chip detection, or methylation fluorescence quantitative PCR.

[0033] In some specific embodiments, the methylation level detection reagent can also be a detection reagent for detecting the average methylation level of a gene fragment.

[0034] In some specific embodiments, the methylation level detection reagent can also be a detection reagent for detecting one or more methylation sites within a gene segment.

[0035] In some specific embodiments, the detection reagents include, but are not limited to, nucleic acid primers and sequencing Tag sequences, for measuring methylation levels by amplification-sequencing.

[0036] In some specific embodiments, the detection reagent includes but is not limited to a chip, wherein the chip is a methylation chip having a probe that specifically binds to a methylation region, and the chip is used to measure the methylation level.

[0037] In some specific embodiments, the detection reagents include, but are not limited to, nucleic acid primers and nucleic acid probes for measuring methylation levels by methylation fluorescence quantitative PCR.

[0038] Furthermore, the detection reagent also includes an internal standard primer and an internal standard probe.

[0039] In a specific embodiment, the target of the internal standard primer and probe is the ACTB gene.

[0040] When the detection reagent includes nucleic acid primers and nucleic acid probes, the detection reagent detects the methylation level of nucleic acid in the sample by methylation fluorescent quantitative PCR.

[0041] In the present invention, "methylation fluorescent quantitative PCR" refers to converting the region to be detected by sulfite or digesting it with a methylation-sensitive restriction endonuclease, and then performing fluorescent quantitative PCR detection using primers and probes specifically designed for the detection target, thereby obtaining the methylation level of the region to be detected.

[0042] The above reagent combination may also include other reagents, specifically, for example, various reagents required for pre-treatment or pre-processing of the sample, such as a sample release agent for extracting sample nucleic acid, a purification agent for purifying sample nucleic acid, bisulfite or bisulfite used for conversion, etc.

[0043] In some specific embodiments, the detection reagents are shown in Table 1. In the following detection reagents, the upstream primer / downstream primer / probe for detecting one target corresponds to a group, and the upstream primer / downstream primer / probe for detecting the targets to be detected is used, that is, this group. Therefore, the detection reagents of the present invention can include any one or more groups of the following primers and probes.

[0044] Table 1

[0045] Primer Name Number Sequence (5’-3’) ME-JAM3-F SEQ ID NO:5 CATGCGCGCGGGGACTAC ME-JAM3-R SEQ ID NO:6 GGCAGCCGAGCGCAGAGC ME-JAM3-P SEQ ID NO:7 CCGCCTCAGCGCCATGTCGAG ME-PCDHGB7-F SEQ ID NO:8 AGTGCAGAGCAAGCGCTGACG ME-PCDHGB7-R SEQ ID NO:9 GCGCAGCCGGGAGCCTC ME-PCDHGB7-P SEQ ID NO:10 CAGCCTCTAGCCTGGGATTCCCTGC ME-SORCS1-F SEQ ID NO:11 CTGGCGGCTGTGGGGGG ME-SORCS1-R SEQ ID NO:12 CGGCTCGCTCCGTCCGG ME-SORCS1-P SEQ ID NO:13 AGGACCCCAACTCCATCCAAG ME-ACTB-F SEQ ID NO:14 GTTGTTACAGGAAGTCCCTTGCC ME-ACTB-R SEQ ID NO:15 GCAATGCTATCACCTCCCCTGTG ME-ACTB-P SEQ ID NO:16 CTTGGGAGAGGACTGGGCCATTCTCC

[0046] In some specific embodiments, the four fluorescence channels adopted by the present invention are FAM, ROX, HEX and CY5 channels, but the actual application is not limited to this, and it can be a combination of any other fluorescence channels; at the same time, different targets can also correspond to different fluorescence channels, such as any fluorescence channel can be used as an internal standard detection channel.

[0047] In a second aspect, the present invention provides a use of the above-described model in the preparation of a kit or device for detecting cervical cancer and high-grade cervical lesions.

[0048] In a third aspect, the present invention provides a device, comprising:

[0049] at least one processor; and

[0050] a memory communicatively connected to at least one of the processors; wherein,

[0051] The memory stores instructions executable by the processor, and the instructions are used to be executed by the processor to implement any of the above-mentioned models for detecting cervical cancer and high-grade cervical lesions.

[0052] In some embodiments, the device further includes at least one input device and at least one output device; in the device, the processor, memory, input device, and output device are connected via a bus.

[0053] In a fourth aspect, a storage medium is provided, wherein the storage medium stores computer instructions, and the computer instructions are used to be executed by the computer to implement the model for detecting cervical cancer and high-grade cervical lesions as described in any one of the above items.

[0054] In some embodiments, the storage medium is a computer-readable storage medium.

[0055] In a fifth aspect, the present invention provides a device, comprising

[0056] A model module, which is used to execute any of the above models for detecting cervical cancer and high-grade cervical lesions; and

[0057] The detection module detects the methylation levels of the JAM3 gene, PCDHGB7 gene and SORCS1 gene.

[0058] In some specific embodiments, the methylation level of the JAM3 gene may be the methylation level of the region of the JAM3 gene as shown in SEQ ID NO: 1.

[0059] In some specific embodiments, the methylation level of the PCDHGB7 gene may be the methylation level of the region of the PCDHGB7 gene as shown in SEQ ID NO:2.

[0060] In some specific embodiments, the methylation level of the SORCS1 gene may be the methylation level of the region of the SORCS1 gene as shown in SEQ ID NO: 3.

[0061] In a sixth aspect, the present invention provides a kit comprising:

[0062] A methylation level detection reagent as described above; and

[0063] The apparatus, device or storage medium as described above.

[0064] Furthermore, the kit also includes, but is not limited to, at least one of a reagent for extracting nucleic acid, a reagent for purifying nucleic acid, and bisulfite.

[0065] Furthermore, the kit also includes a negative sample.

[0066] Specifically, the negative sample is human genomic DNA that has been sequenced to verify that there is no methylation of the target gene.

[0067] Furthermore, the kit also includes dNTPs, Mg 2+ , at least one of a methylation-sensitive restriction endonuclease, a PCR buffer, and a hot-start enzyme.

[0068] Furthermore, the methylation-sensitive restriction endonuclease includes at least one of HpaII, HinP1I and HhaI.

[0069] Furthermore, the range of the final concentration of each component is as follows: Mg 2+ 1~6mM, dNTPs 1~80mM, methylation-sensitive restriction endonuclease 0.01~30U, primer 0.1~40μM, probe 0.1~20μM. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 for the detection of methylation of the composition of the present invention at 0.05 ng / reaction;

[0071] Figure 2 The detection of the composition of the present invention having no non-specific amplification in 20 ng / reaction of non-methylated DNA;

[0072] Figure 3 The figure is the ROC curve analysis result of the composition of the present invention. DETAILED DESCRIPTION

[0073] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.

[0074] Example 1: Screening of methylation genes

[0075] The present invention collects and mines cervical cancer methylation data based on public data source platforms such as TCGA, NCBI, GEO, and EBI ArrayExpress, and uses a variety of bioinformatics to perform differential analysis on the methylation levels of normal cervix or cervical inflammation, cervical intraepithelial neoplasia grade 1 (CIN1), cervical intraepithelial neoplasia grade 2 (CIN2), cervical intraepithelial neoplasia grade 3 (CIN3), and cervical cancer samples, and preliminarily screens out more specific methylation markers. Further, real clinical samples are tested for methylation levels by fluorescent quantitative PCR and analyzed for verification.

[0076] Finally, based on the modeling analysis of cervical exfoliated cell sample data, three genes, JAM3, PCDHGB7 and SORCS1, were identified as optional detection targets. A combination model of these three genes was further constructed for the detection of cervical cancer and high-grade cervical lesions, and its detection performance was evaluated in different populations.

[0077] Example 2: Detection of gene methylation levels of standard products

[0078] Positive samples: Standard methylated human genomic DNA and target gene non-methylated human genomic DNA are mixed and configured, with a concentration of 1ng / μL containing 10% standard methylated human genomic DNA; a concentration of 1ng / μL containing 1% standard methylated human genomic DNA; a concentration of 1ng / μL containing 0.5% standard methylated human genomic DNA;

[0079] Negative samples: human genomic DNA with no target gene methylation verified by sequencing, 2ng / μL;

[0080] Methylation-sensitive restriction endonucleases: including HpaII, HinP1I and HhaI;

[0081] Testing process:

[0082] PCR system configuration: Prepare PCR reaction solution according to the reagent formula in Table 3 below according to different detection targets.

[0083] Table 3

[0084]

[0085]

[0086] The sample was added to the PCR reaction tube at 10 μL / reaction, and then 40 μL of PCR reaction solution was added in sequence. The PCR tube was capped, vortexed to mix, and then centrifuged for 5 seconds.

[0087] Fluorescence PCR reaction and result analysis

[0088] 1) Place the PCR reaction tube into the sample slot of the thermal amplification instrument and set the names of the samples to be tested in the corresponding order.

[0089] 2) Fluorescence detection channel selection: select the FAM channel (Reportere: FAM, Quencher: None) to detect JAM3; select the ROX channel (Reportere: ROX, Quencher: None) to detect SORCS1; select the HEX channel (Reportere: ROX, Quencher: None) to detect PCDHGB7; select the CY5 channel (Reportere: CY5, Quencher: None) as the internal standard to detect the housekeeping gene ACTB;

[0090] 3) Fluorescence quantitative PCR reaction conditions are as shown in Table 4:

[0091] Table 4

[0092]

[0093] 4) Result analysis

[0094] After the reaction is finished, the instrument automatically saves the results, which can be automatically analyzed using the instrument's own software (you can also manually adjust the baseline start value, end value, and threshold line value for analysis). The intersection of the amplification curve and the threshold line is called Ct (i.e., cycle threshold, which refers to the cycle value experienced when the fluorescent signal in the PCR reaction tube reaches the set threshold). Figures 1-2 As shown, the detection reagent provided by the present invention is 0.05ng / reaction ( Figure 1 ), no non-specific amplification in 20 ng / reaction of non-methylated DNA ( Figure 2 ).

[0095] Example 3: Detection performance of the model and composition 1 of the present invention for high-grade cervical lesions

[0096] From the 2372 cervical exfoliated cell samples collected from HPV-positive people, 1223 clinical samples with cytological examination results were randomly selected according to the distribution ratio of different cervical lesions in the Chinese HPV-positive population reported in literature and previous studies (including 8 cervical cancer [CC] patients, 172 CIN3 patients, 192 CIN2 patients, 175 CIN1 patients, and 676 Normal patients) for verification and detection of the composition of the present invention, and a logistic regression algorithm model was obtained based on the results obtained.

[0097] The nucleic acid extraction was performed using the S10016 nucleic acid extraction reagent of Shengxiang Biotechnology in combination with the extraction instrument natch48. According to the process of Example 2, the nucleic acid sample was digested and PCR amplified in the same reaction tube. Based on the amplification results, the ΔCt value (Ct (target gene) - Ct (reference gene)) was calculated, and logistic regression fitting and ROC curve analysis were performed to obtain the prediction model:

[0098] ① Taking CIN2+ as the outcome variable:

[0099]

[0100] When the P value calculated by the prediction model is greater than or equal to 0.295, it is judged as positive; when it is less than 0.295, it is judged as negative.

[0101] ② Taking CIN3+ as the outcome variable:

[0102]

[0103] When the P value calculated by the prediction model is greater than or equal to 0.103, it is judged as positive; when it is less than 0.103, it is judged as negative.

[0104] The ROC curve analysis results of prediction model ① and prediction model ② are as follows Figure 3 As shown, the AUC value of the overall model is displayed, and the optimal cutoff value for this population is indicated.

[0105] The methylation test results were judged positively with the optimal cutoff value, and the detection results of high-grade cervical lesions and cervical cancer by prediction model ① and prediction model ② are shown in Tables 5 to 7. Among them, CIN3+ includes CIN3 and cervical cancer, and CIN2+ includes cervical cancer, CIN3 and CIN2. The results show that the sensitivity and specificity of the composition of the present invention for the detection of high-grade cervical lesions CIN2 and CIN3 and cervical cancer (CIN2+) are 69.9% and 88.8%, respectively, and the sensitivity and specificity for the detection of CIN3 and cervical cancer (CIN3+) are 85.0% and 81.8%, respectively.

[0106] Table 5

[0107]

[0108] After the composition of the present invention was calculated and classified by prediction model ①, the detection results of cervical cancer, different stages of cervical precancerous lesions, cervical inflammation or normal cervix in HPV-positive people are shown in Table 6 below.

[0109] Table 6

[0110]

[0111]

[0112] Among them, the methylation gene detection result refers to the result of the methylation detection Ct value of the composition of the present invention after calculation and classification by the prediction model ①, CC refers to cervical cancer, CIN3 refers to cervical intraepithelial neoplasia grade 3, CIN2 refers to cervical intraepithelial neoplasia grade 2, CIN1 refers to cervical intraepithelial neoplasia grade 1, and Normal refers to normal cervix or cervical inflammation. The methylation detection positive rate refers to the proportion of methylation positive results of the composition of the present invention in different lesion levels. trend Refers to the Cochran-Armitage trend test results, P trend <0.05 indicates that in the HPV-positive population, the methylation-positive rate of the composition of the present invention gradually increases with the deepening of the severity of cervical lesions, indicating that the composition of the present invention may indicate the occurrence and development of cervical lesions.

[0113] Similarly, after the composition of the present invention was calculated and classified by prediction model ②, the detection results of cervical cancer, different stages of cervical precancerous lesions, cervical inflammation or normal cervix in HPV-positive people are shown in Table 7 below.

[0114] Table 7

[0115]

[0116] Among them, the methylation gene detection result refers to the result after the methylation detection Ct value of the composition of the present invention is calculated and classified by the prediction model ②, CC refers to cervical cancer, CIN3 refers to cervical intraepithelial neoplasia grade 3, CIN2 refers to cervical intraepithelial neoplasia grade 2, CIN1 refers to cervical intraepithelial neoplasia grade 1, and Normal refers to normal cervix or cervical inflammation. The methylation detection positive rate refers to the degree of consistency between the methylation positive result of the composition of the present invention and the pathological result. trend Refers to the Cochran-Armitage trend test results, P trend <0.05 indicates that in the HPV-positive population, the methylation-positive rate of the composition of the present invention gradually increases with the deepening of the severity of cervical lesions, indicating that the composition of the present invention may indicate the occurrence and development of cervical lesions.

Claims

1. A model for detecting cervical cancer and high-grade cervical lesions: The model is a diagnostic model for cervical cancer and high-grade cervical lesions constructed based on the JAM3 gene, PCDHGB7 gene and SORCS1 gene using logistic regression, support vector machine, random forest, neural network, LASSO regression or ridge regression model.

2. The model according to claim 1, characterized in that The model includes: a CIN2+ diagnostic model and / or a CIN3+ diagnostic model.

3. The model according to claim 2, characterized in that The CIN2+ diagnostic model is: Among them, X1 is the methylation level of the JAM3 gene; X2 is the methylation level of the PCDHGB7 gene; X3 is the methylation level of the SORCS1 gene; When the P value calculated by the prediction model is greater than or equal to 0.295, it is judged as positive; when it is less than 0.295, it is judged as negative.

4. The model according to claim 2, characterized in that The CIN3+ diagnostic model is: Among them, X1 is the methylation level of the JAM3 gene; X2 is the methylation level of the PCDHGB7 gene; X3 is the methylation level of the SORCS1 gene; When the P value calculated by the prediction model is greater than or equal to 0.103, it is judged as positive; when it is less than 0.103, it is judged as negative.

5. The model according to any one of claims 1 to 4, characterized in that The methylation level of the JAM3 gene is the methylation level of the region of the JAM3 gene as shown in SEQ ID NO: 1; the methylation level of the PCDHGB7 gene is the methylation level of the region of the PCDHGB7 gene as shown in SEQ ID NO: 2; the methylation level of the SORCS1 gene is the methylation level of the region of the SORCS1 gene as shown in SEQ ID NO:

3.

6. Use of the model according to any one of claims 1 to 5 in preparing a kit or device for detecting cervical cancer and high-grade cervical lesions.

7. A device comprising: at least one processor; as well as a memory communicatively connected to at least one of the processors; wherein, The memory stores instructions executable by the processor, and the instructions are used to be executed by the processor to implement the model for detecting cervical cancer and high-grade cervical lesions according to any one of claims 1 to 5.

8. A storage medium storing computer instructions, wherein the computer instructions are used to be executed by the computer to implement the model for detecting cervical cancer and high-grade cervical lesions according to any one of claims 1 to 5.

9. A device comprising A model module, which is used to execute the model for detecting cervical cancer and high-grade cervical lesions according to any one of claims 1 to 5; and The detection module detects the methylation levels of the JAM3 gene, PCDHGB7 gene, and SORCS1 gene.

10. A kit comprising: The device or apparatus or storage medium according to any one of claims 7 to 9; as well as A methylation level detection reagent for detecting the methylation levels of the JAM3 gene, PCDHGB7 gene, and SORCS1 gene.

Citation Information

Patent Citations

  • Gene methylation marker combination and screening model for screening high-grade cervical lesions

    CN116121384A

  • Cervical cancer DNA methylation marker and application thereof

    CN117305447A

  • Kit for detecting methylation of cervical cancer

    CN117757946A

  • Application of detection primer probe group for combined diagnosis of SORCS1 gene methylation and PAX1 gene methylation in preparation of cervical cancer diagnosis product

    CN117904303A

Cited By

  • Methylation marker combination for detecting cervical cancer and / or precancerous lesions of cervical cancer as well as application, product, detection device, computer readable storage medium, electronic terminal and computer program of methylation marker combination

    CN119842908A

  • A combination of DNA methylation markers for detecting CIN3+ and its applications

    CN123063527A